$9.12
3.28% yesterday
NYSE, Dec 03, 10:18 pm CET
ISIN
VGG111961055
Symbol
BHVN

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$9.12
-5.73 38.59% 1M
-6.66 42.21% 6M
-28.23 75.58% YTD
-34.56 79.12% 1Y
-7.20 44.12% 3Y
-77.91 89.52% 5Y
-8.38 47.89% 10Y
-8.38 47.89% 20Y
NYSE, Closing price Wed, Dec 03 2025
+0.29 3.28%
ISIN
VGG111961055
Symbol
BHVN
Industry

Key metrics

Basic
Market capitalization
$965.4m
Enterprise Value
$705.2m
Net debt
positive
Cash
$260.2m
Shares outstanding
105.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 207.0
EV/Sales
- | 151.2
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
68.8%
Return on Equity
-199.9%
ROCE
-267.7%
ROIC
-725.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $4.7m
EBITDA
$-782.8m | $-810.1m
EBIT
$-792.6m | $-863.3m
Net Income
$-780.1m | $-836.6m
Free Cash Flow
$-650.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
7.0% | 7.7%
EBIT
6.6% | 2.5%
Net Income
3.0% | 1.2%
Free Cash Flow
-22.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -17,369.6%
EBIT
-
Net
- | -17,937.0%
Free Cash Flow
-
More
EPS
$-7.4
FCF per Share
$-6.1
Short interest
10.9%
Employees
256
Rev per Employee
$0.0
Show more

Is Biohaven Pharmaceutical Holding Company Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

22x Buy
92%
2x Hold
8%

Analyst Opinions

24 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy
92%
Hold
8%

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 112 112
31% 31%
-
- Research and Development Expense 681 681
11% 11%
-
-783 -783
7% 7%
-
- Depreciation and Amortization 9.81 9.81
35% 35%
-
EBIT (Operating Income) EBIT -793 -793
7% 7%
-
Net Profit -780 -780
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biohaven Pharmaceutical Holding Company Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Positive
MarketBeat
14 days ago
When corporate executives make multi-million-dollar personal investments in the company they lead, it is one of the most potent signals an investor can receive. At Biohaven NYSE: BHVN, that signal has just been sent loud and clear.
Neutral
The Motley Fool
15 days ago
On November 17, 2025, Biohaven's Chief Accounting Officer, George Clark, acquired 17,000 shares of company stock. Mr. Clark's purchase was valued at approximately $144,800.
More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office Virgin Islands, British
CEO Vladimir Coric
Employees 256
Founded 2022
Website www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today